- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting...
BOSTON, Aug. 29, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today released the following notice: UNITED STATES DISTRICT COURTNORTHERN DISTRICT OF...
In vitro findings reveal Telomir-1's dual action: targeting DNA methylation switches and cutting into the Wnt "fuel line" that drives...
LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of...
CHICAGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company...
LAVAL, QC AND CUPERTINO, CA / ACCESS Newswire / August 26, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global,...
Media ReleaseCOPENHAGEN, Denmark; August 26, 2025 Breakthrough Therapy Designation granted to Rina-S for the treatment of adult patients with recurrent...
Current Clinical Trial Focus is MSS Colorectal Cancer, Ovarian Clear-Cell Carcinoma, and Soft-Tissue SarcomaDENVER, Aug. 25, 2025 (GLOBE NEWSWIRE) --...
Proprietary platform is built on one of the largest multimodal oncology datasets, including 250,000+ tumor exomes, 1 million+ plasma timepoints,...
Proprietary platform is built on one of the largest multimodal oncology datasets, including 250,000+ tumor exomes, 1 million+ plasma timepoints,...
Research seeks to advance discovery and development of treatments for ALS LOS ANGELES, Aug. 21, 2025 /PRNewswire/ -- The ALS...
Edge vision + multimodal, multi-model orchestration deliver real-time, hyper-personalized support at the bedside BERKELEY, Calif., Aug. 21, 2025 /PRNewswire/ --...
In this free webinar, learn how enhanced precision and efficiency through advanced AI tools enable rapid and accurate design of...
BOSTON, Aug. 20, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today...
Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies...
Assessment of feasibility for use of Parsortix derived circulating tumour cell (CTC) DNA with Myriad Genetics' existing tissue-based diagnostic test...
Empowering Emerging Leaders Through Research-Backed Training and Measurable Growth CONCORD, Calif., Aug. 19, 2025 /PRNewswire/ -- Center for Social Dynamics...
PLANO, Texas, Aug. 19, 2025 /PRNewswire/ -- StaffDNA today unveiled a powerful new document storage and management platform designed to transform...
RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2025 /PRNewswire/ -- Calidar, Inc., an innovative start-up in precision diagnostic imaging, today announced...
Collaboration Extends Global Reach of High-Performance Genomic Sequencing on the UG 100™ Platform FREMONT, Calif. and HOUSTON, Aug. 19, 2025...